Anixa Biosciences (ANIX) Projected to Release Earnings on Wednesday

Anixa Biosciences (NASDAQ:ANIX) is expected to release its Q3 2026 results before the market opens on Wednesday, September 9th. Analysts expect Anixa Biosciences to post earnings of ($0.08) per share for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Wednesday, September 16, 2026 at 4:00 PM ET.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. On average, analysts expect Anixa Biosciences to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Anixa Biosciences Price Performance

NASDAQ:ANIX opened at $3.07 on Monday. Anixa Biosciences has a 52 week low of $2.32 and a 52 week high of $5.46. The firm has a 50 day moving average of $3.35 and a 200 day moving average of $2.99. The stock has a market capitalization of $104.44 million, a price-to-earnings ratio of -9.90 and a beta of 0.51.

Insider Buying and Selling at Anixa Biosciences

In other news, CEO Amit Kumar acquired 21,000 shares of the business’s stock in a transaction dated Friday, June 12th. The shares were acquired at an average cost of $2.50 per share, with a total value of $52,500.00. Following the completion of the acquisition, the chief executive officer owned 630,812 shares of the company’s stock, valued at approximately $1,577,030. This trade represents a 3.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders bought 50,024 shares of company stock valued at $148,971 over the last quarter. 26.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of ANIX. NewEdge Advisors LLC acquired a new stake in Anixa Biosciences during the 2nd quarter valued at approximately $33,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of Anixa Biosciences by 2,000.0% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after acquiring an additional 10,000 shares during the period. Cetera Investment Advisers purchased a new position in shares of Anixa Biosciences during the fourth quarter worth $35,000. Benjamin Edwards Inc. purchased a new position in shares of Anixa Biosciences during the second quarter worth $37,000. Finally, Marshall Wace LLP acquired a new position in Anixa Biosciences during the second quarter valued at $39,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on ANIX. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Zacks Research lowered shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Anixa Biosciences presently has a consensus rating of “Hold” and a consensus price target of $8.50.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.